Published in Arch Neurol on April 01, 1991
Finding the Optimum Regimen for Duchenne Muscular Dystrophy (FOR-DMD) | NCT01603407
The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve (2013) 2.47
Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology (2011) 1.86
Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRS. Neurology (2014) 1.79
Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum (2007) 1.72
The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve (2013) 1.63
Myonuclear apoptosis in dystrophic mdx muscle occurs by perforin-mediated cytotoxicity. J Clin Invest (1997) 1.61
The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve (2013) 1.48
Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology (2016) 1.41
Therapeutic advances in muscular dystrophy. Ann Neurol (2013) 1.17
Emerging drugs for Duchenne muscular dystrophy. Expert Opin Emerg Drugs (2012) 1.11
Relationship between clinical outcome measures and parent proxy reports of health-related quality of life in ambulatory children with Duchenne muscular dystrophy. J Child Neurol (2010) 1.10
Worsening of cardiomyopathy using deflazacort in an animal model rescued by gene therapy. PLoS One (2011) 1.05
Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. Hum Mol Genet (2014) 1.05
The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy. J Neurol Neurosurg Psychiatry (2006) 1.02
Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial. Orphanet J Rare Dis (2013) 1.01
Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy. Phys Med Rehabil Clin N Am (2012) 0.98
Therapeutics in duchenne muscular dystrophy. NeuroRx (2006) 0.98
Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. Neurology (2015) 0.98
Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy. Acta Myol (2012) 0.97
Online self-report data for duchenne muscular dystrophy confirms natural history and can be used to assess for therapeutic benefits. PLoS Curr (2014) 0.93
Molecular and cell-based therapies for muscle degenerations: a road under construction. Front Physiol (2014) 0.92
Assessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging options. Ther Clin Risk Manag (2015) 0.91
Prednisolone improves walking in Japanese Duchenne muscular dystrophy patients. J Neurol (2013) 0.91
Prednisone 10 days on/10 days off in patients with Duchenne muscular dystrophy. J Neurol (2009) 0.91
Human skeletal muscle xenograft as a new preclinical model for muscle disorders. Hum Mol Genet (2014) 0.90
Approaching a new age in Duchenne muscular dystrophy treatment. Neurotherapeutics (2008) 0.88
Deflazacort for the treatment of Duchenne Dystrophy: a systematic review. BMC Neurol (2003) 0.88
Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy: Treatment Duration and Time to Loss of Ambulation. J Child Neurol (2014) 0.85
Current and emerging treatment strategies for Duchenne muscular dystrophy. Neuropsychiatr Dis Treat (2016) 0.83
Increased muscle expression of interleukin-17 in Duchenne muscular dystrophy. Neurology (2012) 0.81
Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology (2016) 0.81
Current Translational Research and Murine Models For Duchenne Muscular Dystrophy. J Neuromuscul Dis (2016) 0.80
The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies. Int J Exp Pathol (2006) 0.80
What can Duchenne Connect teach us about treating Duchenne muscular dystrophy? Curr Opin Neurol (2015) 0.79
Noncoding RNAs: emerging players in muscular dystrophies. Biomed Res Int (2014) 0.79
Myotonic dystrophy health index: Correlations with clinical tests and patient function. Muscle Nerve (2015) 0.78
The Correlation of Skeletal and Cardiac Muscle Dysfunction in Duchenne Muscular Dystrophy. J Neuromuscul Dis (2016) 0.75
Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy. J Pediatr (2016) 0.75
Dystrophic Cardiomyopathy-Potential Role of Calcium in Pathogenesis, Treatment and Novel Therapies. Genes (Basel) (2017) 0.75
11β-Hydroxysteroid dehydrogenase type 1 within muscle protects against the adverse effects of local inflammation. J Pathol (2016) 0.75
Effect of the IL-1 Receptor Antagonist Kineret® on Disease Phenotype in mdx Mice. PLoS One (2016) 0.75
Retrospective cohort study comparing the efficacy of prednisolone and deflazacort in children with muscular dystrophy: A 6 years' experience in a South Indian teaching hospital. Indian J Orthop (2016) 0.75
Electrical impedance myography for assessment of Duchenne muscular dystrophy. Ann Neurol (2017) 0.75
Disease Progression Modeling: Key Concepts and Recent Developments. Curr Pharmacol Rep (2016) 0.75
Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol (1987) 9.10
Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol (2001) 8.88
Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood (1998) 6.81
Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol (1998) 5.93
Muscle fiber types: how many and what kind? Arch Neurol (1970) 5.51
Strategies for reducing coronary heart disease and desirable limits for blood lipid concentrations: guidelines of the British Hyperlipidaemia Association. Br Med J (Clin Res Ed) (1987) 5.01
The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet (1997) 4.86
Cancer linked to Alzheimer disease but not vascular dementia. Neurology (2009) 4.83
Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am J Hum Genet (1997) 4.29
Three "myosin adenosine triphosphatase" systems: the nature of their pH lability and sulfhydryl dependence. J Histochem Cytochem (1970) 3.77
Hippocampal morphometry in schizophrenia by high dimensional brain mapping. Proc Natl Acad Sci U S A (1998) 3.72
The AD8: a brief informant interview to detect dementia. Neurology (2005) 3.65
Assessing family sharing of diabetes responsibilities. J Pediatr Psychol (1990) 3.43
Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med (1989) 3.32
Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum Mol Genet (2001) 3.27
Preclinical detection of Alzheimer's disease: hippocampal shape and volume predict dementia onset in the elderly. Neuroimage (2005) 3.21
Difference in relapse rates of duodenal ulcer after healing with cimetidine or tripotassium dicitrato bismuthate. Lancet (1981) 2.95
The histographic analysis of human muscle biopsies with regard to fiber types. 1. Adult male and female. Neurology (1969) 2.94
Normal brain in human newborns: apparent diffusion coefficient and diffusion anisotropy measured by using diffusion tensor MR imaging. Radiology (1998) 2.81
Inclusion body myositis and myopathies. Ann Neurol (1995) 2.68
Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol (1990) 2.66
Mutations in the tail domain of DYNC1H1 cause dominant spinal muscular atrophy. Neurology (2012) 2.56
Correlating phenotype and genotype in the periodic paralyses. Neurology (2004) 2.55
Risk of seizures and encephalopathy after immunization with the diphtheria-tetanus-pertussis vaccine. JAMA (1990) 2.54
Reliability of the Washington University Clinical Dementia Rating. Arch Neurol (1988) 2.48
The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation (1984) 2.45
The prevalence and correlates of fear of falling in elderly persons living in the community. Am J Public Health (1994) 2.37
Early DAT is distinguished from aging by high-dimensional mapping of the hippocampus. Dementia of the Alzheimer type. Neurology (2000) 2.31
Hyperlipidaemia, hypertension, and coronary heart disease. Lancet (1995) 2.28
Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design. Neurology (2011) 2.28
Neurological complications of immunization. Ann Neurol (1982) 2.25
Improved evaluation of the location and mechanism of mitral valve regurgitation with a systematic transesophageal echocardiography examination. Anesth Analg (1999) 2.23
Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med (1977) 2.23
Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med (1986) 2.22
A prospective study of cognitive function and onset of dementia in cognitively healthy elders. Arch Neurol (1998) 2.22
A novel cDNA detects homozygous microdeletions in greater than 50% of type I spinal muscular atrophy patients. Nat Genet (1995) 2.17
Dystrophin expression and somatic reversion in prednisone-treated and untreated Duchenne dystrophy. CIDD Study Group. Neurology (1991) 2.16
TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry (2008) 2.07
Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve (1981) 2.06
Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history. Muscle Nerve (1983) 1.99
Three mouse models of muscular dystrophy: the natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin alpha2-deficient mice. Neuromuscul Disord (2001) 1.97
Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann Neurol (1994) 1.97
The histographic analysis of human muscle biopsies with regard to fiber types. 4. Children's biopsies. Neurology (1969) 1.93
Myasthenia gravis: passive transfer from man to mouse. Science (1975) 1.90
Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology (1989) 1.90
Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol (1989) 1.88
Very Early Constraint-Induced Movement during Stroke Rehabilitation (VECTORS): A single-center RCT. Neurology (2009) 1.87
Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology (2011) 1.86
Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry (2002) 1.84
The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis. Arch Neurol (1991) 1.81
Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. Am J Hum Genet (1992) 1.81
Effects of PMP22 duplication and deletions on the axonal cytoskeleton. Ann Neurol (1999) 1.81
Broadband neural encoding in the cricket cercal sensory system enhanced by stochastic resonance. Nature (1996) 1.80
The stomatogastric nervous system: structure and function of a small neural network. Prog Neurobiol (1976) 1.80
Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ (2000) 1.80
The relationship between the metabolism of ribavirin and its proposed mechanism of action. Ann N Y Acad Sci (1977) 1.79
The clinical correlates of high-titer IgG anti-GM1 antibodies. Ann Neurol (1994) 1.79
Expansion of the myotonic dystrophy CTG repeat reduces expression of the flanking DMAHP gene. Nat Genet (1997) 1.76
Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet (2006) 1.76
Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months) Neurology (1993) 1.75
Pretreatment blood pressure as a predictor of 21-year mortality. Am J Hypertens (2000) 1.75
Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology (2001) 1.75
A randomized clinical trial of continuous-flow nitrous oxide and midazolam for sedation of young children during laceration repair. Ann Emerg Med (2001) 1.74
A clinical trial of creatine in ALS. Neurology (2004) 1.73
Interlaboratory histopathologic assessment of Alzheimer neuropathology: different methodologies yield comparable diagnostic results. Alzheimer Dis Assoc Disord (1993) 1.72
Myotonic dystrophy patients have larger CTG expansions in skeletal muscle than in leukocytes. Ann Neurol (1994) 1.72
Myotonic dystrophy with no trinucleotide repeat expansion. Ann Neurol (1994) 1.68
Intrarater reliability of manual muscle test (Medical Research Council scale) grades in Duchenne's muscular dystrophy. Phys Ther (1992) 1.67
Identification of two point mutations and a one base deletion in exon 19 of the dystrophin gene by heteroduplex formation. Hum Mol Genet (1993) 1.67
Rapid killing of single neurons by irradiation of intracellularly injected dye. Science (1979) 1.67
Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology (2010) 1.67
Temporal encoding in nervous systems: a rigorous definition. J Comput Neurosci (1995) 1.67
The natural history of acute confusional migraine. Arch Neurol (1978) 1.66
The histographic analysis of human muscle biopsies with regard to fiber types. 2. Diseases of the upper and lower motor neuron. Neurology (1969) 1.64
NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology (2005) 1.63
Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D. Neurology (2008) 1.63
Some comments on the histochemical characterization of muscle adenosine triphosphatase. J Histochem Cytochem (1969) 1.63
Painful sensory neuropathy: prospective evaluation using skin biopsy. Neurology (1999) 1.62
Toxic polyneuropathy due to methyl n-butyl ketone. An industrial outbreak. Arch Neurol (1975) 1.62
Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology (1998) 1.61
Relapse of duodenal ulcer: does it matter which drug is used in initial treatment? Br Med J (Clin Res Ed) (1986) 1.60
Comparison of fentanyl/midazolam with ketamine/midazolam for pediatric orthopedic emergencies. Pediatrics (1998) 1.60
Accuracy of predonation Hct sampling affects donor safety, eligibility, and deferral rates. Transfusion (2001) 1.60
Alzheimer disease and cancer. Neurology (2005) 1.60